Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Scientists hail drug that launches two-pronged attack on breast cancer cells

  • Comment

Scientists have proved for the first time that a breast cancer drug can simultaneously attack cancer cells in two different ways.

Researchers from the Breakthrough Breast Cancer Research Centre at the Institute of Cancer Research hope the find can help in the development of more two-in-one treatments.

This would mean that breast cancer patients would potentially take fewer drugs in future years.

The team demonstrated that an experimental compound known as PTK/ZK acted as an ‘aromatase inhibitor’, preventing the growth of hormone-sensitive breast cancers relying on oestrogen for survival.

This accounts for more than 70% of breast cancer cases.

The compound was originally developed as an ‘angiogenesis inhibitor’ to block a tumour’s blood supply and slow its growth.

Dr Susana Banerjee, a member of the team, said: ‘Developing one drug that attacks a tumour in two completely different ways may provide a better approach to fighting breast cancer.

‘Not only does this approach have the potential to boost the effectiveness of existing drugs, it could also mean that patients need to take fewer drugs to treat tumours.’

The laboratory study was funded by Avon Cosmetics, The Mary-Jean Mitchell Green Foundation and Novartis Pharma in a joint venture and is published in the current issue of Cancer Research.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.